Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Ceriello, Antonio ^a   Novials, Anna ^a   Ortega, Emilio ^a   Canivell, Silvia ^a   Pujadas, Gemma ^a   La Sala, Lucia ^a   Bucciarelli, Loredana ^b   Rondinelli, Maurizio ^b   Genovese, Stefano ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Diabetes Mellitus; Endothelial Dysfunction; GLP 1; Hyperglycemia; Hypoglycemia; Oxidative Stress

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ASCORBIC ACID; GLUCAGON LIKE PEPTIDE 1; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; 3-NITROTYROSINE; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIDIABETIC AGENT; ANTIOXIDANT; AUTACOID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; ICAM1 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; PROSTAGLANDIN F2 ALPHA; TYROSINE;

ADULT; AMINO ACID BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIA; MALE; OXIDATIVE STRESS; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; TREATMENT OUTCOME; VASODILATATION; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INFUSION; METABOLISM; PATHOPHYSIOLOGY; REPERFUSION INJURY; TIME; YOUNG ADULT;

ADULT; ANTIOXIDANTS; ASCORBIC ACID; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DINOPROST; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION; INFLAMMATION MEDIATORS; INFUSIONS, PARENTERAL; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; OXIDATIVE STRESS; REPERFUSION INJURY; TIME FACTORS; TREATMENT OUTCOME; TYROSINE; VASODILATION; YOUNG ADULT;

EID: 84879423009     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-97     Document Type: Article

References (34)

1. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab Res Rev 2008, 24:353-363. 10.1002/dmrr.865, 18461635.
2. Singh P, Jain A, Kaur G. Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol Cell Biochem 2004, 260:153-159.
3. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010, 33:1529-1535. 10.2337/dc09-0354, 2890354, 20587723.
4. Wang J, Alexanian A, Ying R, Kizhakekuttu TJ, Dharmashankar K, Vasquez-Vivar J, Gutterman DD, Widlansky ME. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol 2012, 32:712-720. 10.1161/ATVBAHA.111.227389, 3319449, 22207730.
5. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070. 10.1161/CIRCRESAHA.110.223545, 2996922, 21030723.
6. Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil 2010, 17(Suppl 1):S15-S19.
7. Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism 2009, 58:443-448. 10.1016/j.metabol.2008.10.018, 19303962.
8. Nandish S, Wyatt J, Bailon O, Smith M, Oliveros R, Chilton R. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol 2011, 108(3 Suppl):42B-51B.
9. Suh SW, Gum ET, Hamby AM, Chan PH, Swanson RA. Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. J Clin Invest 2007, 117:910-918. 10.1172/JCI30077, 1838937, 17404617.
10. Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, Bonfigli AR, Esposito K, Giugliano D. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes 2012, 61:2993-2997. 10.2337/db12-0224, 22891214.
11. Taegtmeyer H, Dilsizian V. Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med 2008, 5(Suppl 2):S42-S48.
12. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010, 123(Suppl. 3):S28-S37.
13. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes 2010, 59:1117-1125. 10.2337/db09-1899, 2857890, 20427697.
14. Issa CM, Azar ST. Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Curr Diab Rep 2012, 12:560-567. 10.1007/s11892-012-0291-6, 22767380.
15. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010, 123(Suppl. 3):S19-S27.
16. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215. 10.1152/ajpendo.00237.2004, 15353407.
17. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an " endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 2011, 34:697-702. 10.2337/dc10-1949, 3041210, 21273492.
18. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010, 30:1407-1414. 10.1161/ATVBAHA.110.206425, 20448207.
19. Chinda K, Chattipakorn S, Chattipakorn N. Cardioprotective effects of incretin during ischaemia-reperfusion. Diab Vasc Dis Res 2012, 9:256-269. 10.1177/1479164112440816, 22496404.
20. Green CJ, Henriksen TI, Pedersen BK, Solomon TP. Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS One 2012, 7:e44284. 10.1371/journal.pone.0044284, 3429413, 22937169.
21. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307. 10.1172/JCI116186, 330027, 8423228.
22. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001, 44:834-838. 10.1007/s001250100529, 11508267.
23. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965. 10.1161/01.CIR.0000120505.91348.58, 14981009.
24. Birnbaum Y, Ye Y, Bajaj M. Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. Metab Syndr Relat Disord 2012, 10:387-390. 10.1089/met.2012.0095, 22985024.
25. Dokken BB, Piermarini CV, Teachey MK, Gura MT, Dameff CJ, Heller BD, Krate J, Ashgar AM, Querin L, Mitchell JL, Hilwig RW, Kern KB. Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects. Am J Physiol Heart Circ Physiol 2013, 304:H538-H546. 10.1152/ajpheart.00282.2012, 23241323.
26. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care 2009, 32(Suppl 2):S232-S236. 2811469, 19875557.
27. Tesauro M, Schinzari F, Adamo A, Rovella V, Martini F, Mores N, Barini A, Pitocco D, Ghirlanda G, Lauro D, Campia U, Cardillo C. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the Metabolic Syndrome. Diabetes Care 2013, 36:683-689. 10.2337/dc12-0763, 23069838.
28. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64. 10.1186/1475-2840-11-64, 3434036, 22681705.
29. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013, 5:6. 10.1186/1758-5996-5-6, 3607889, 23415113.
30. Orchard TJ, Costacou T. When are type 1 diabetic patients at risk for cardiovascular disease?. Curr Diab Rep 2010, 10:48-54. 10.1007/s11892-009-0089-3, 20425067.
31. Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, Witte DR, Fuller JH, Cavallo Perin P, Bruno G. Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study. Diabetes Care 2012, 35:1598-1604. 10.2337/dc11-1531, 3379603, 22584135.
32. Snell-Bergeon JK, Nadeau K. J Cardiovascular Disease Risk in Young People with Type 1 Diabetes. Cardiovasc Transl Res 2012, 5:446-462.
33. Giménez M, López JJ, Castell C, Conget I. Hypoglycaemia and cardiovascular disease in Type 1 Diabetes. Results from the Catalan National Public Health registry on insulin pump therapy. Diabetes Res Clin Pract 2012, 96:e23-e25. 10.1016/j.diabres.2012.01.014, 22306058.
34. Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S. GLP-1 reduces endothelial dysfunction, inflammation and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 2013, Apr 5. [Epub ahead of print].